ClinicalTrials.gg
CompletedNCT06545500Updated Feb 9, 2026Results posted

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

A Phase 2 interventional study of Glycopyrrolate (85 μg) and Glycopyrrolate (42.5 μg) in Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA. Completed at 7 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
53rd of 73
46 · median 152
Started
2024
with 2 others
Phase 2
19 of 73
none open now
Registered
68th of 73
by date
Lead sponsor
3 of 73
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 53rd largest by enrollment, is one of 3 that started in 2024, is one of 19 in phase 2, and was the 68th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice daily via standard jet nebulizer over three 1-week active treatment periods and one 1-week placebo period in subjects with chronic obstructive pulmonary disease (COPD).

Read the detailed description

Participants enrolled will be expected to participate for approximately 10 weeks;1-2 weeks for screening, four 1-week treatment periods separated by 1 week of washout between each treatment, and 1 week of follow-up. Participants will be randomized to a treatment sequence, 1-4, which will determine the order that they receive the dose levels during the four treatment periods of the study. Neither participants nor study staff will know which dose a participant is receiving in any given treatment period. All participants will receive all 4 dose levels and it is expected that each participant completes all four treatment periods in their assigned sequence. The primary objective of this study is to evaluate the bronchodilator effect of twice daily inhaled glycopyrrolate solution over a dose range administered by standard jet nebulizer in subjects with COPD on Day 7, to support the selection of the glycopyrrolate doses for further clinical development in a fixed-dose combination with ensifentrine.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males are eligible to participate if they agree to use from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication.
  • Females are eligible to participate if they are not pregnant, not breastfeeding, and ≥ 1 of the following conditions apply:

    1. Not a woman of (WOCBP) OR
    2. A WOCBP who agrees to follow the contraceptive guidance from Screening and throughout the study and for at least 30 days after the last dose of blinded study medication.
  • Current or former cigarette smokers with a history of cigarette smoking ≥ 10 pack years at Screening [number of pack years = (number of cigarettes per day / 20) × number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Pipe and/or cigar use cannot be used to calculate pack-year history. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Screening. Smoking cessation programs are permitted during the study.
  • Subjects with an established clinical history of as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD.
  • Post-bronchodilator (4 puffs of salbutamol) spirometry at Screening demonstrating both the following:

    1. /forced vital capacity (FVC) ratio of \< 0.70 AND
    2. FEV1 ≥ 30 % and ≤ 70% of predicted normal
  • A posterior-anterior chest x-ray (CXR) at Screening or within 12 months prior to Screening showing no abnormalities unrelated to COPD. If a CXR within the past 12 months is not available but a computed tomography (CT) scan within the same time period is available, the CT scan may be reviewed in place of a CXR.
  • Capable of withdrawing from short-acting bronchodilators for 4 hours prior to spirometry testing and from BID LABA ± ICS therapy for 24 hours prior to spirometry.
  • Capable of using the study nebulizer correctly.
  • Ability to perform acceptable spirometry in accordance with ATS/ERS guidelines
  • Willing and able to attend all study visits and adhere to all study assessments and procedures.

Exclusion criteria

Exclusion Criteria:

  • Concomitant pulmonary disease other than (i.e., asthma, tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnea (unless controlled with stable continuous positive airway pressure [CPAP] use), known alpha-1 antitrypsin deficiency, core pulmonale or other non-specific pulmonary disease).
  • Within 6 months prior to Screening:

    1. COPD exacerbation requiring hospitalization.
    2. Use of therapies for COPD exacerbation (e.g., oral, intravenous, or intramuscular ).
  • Lower respiratory tract infection within 6 weeks of Screening or an active infection at Screening.
  • History of life-threatening COPD, including Intensive Care Unit admission and/or requiring intubation.
  • Previous lung resection or lung reduction surgery within 1-year of Screening.
  • Long term oxygen use defined as oxygen therapy prescribed for greater than 12 hours per day. As needed oxygen use (≤ 12 hours per day) is not exclusionary.
  • Severe comorbidities including unstable cardiac, or any other clinically significant medical conditions including uncontrolled diseases that would, in the opinion of the Investigator, preclude the subject from safely completing the required tests or the study, or is likely to result in disease progression that would require withdrawal of the subject.
  • History of or clinically significant on-going bladder outflow obstruction or history of catheterization for relief of bladder outflow obstruction within the previous 6 months.
  • History of narrow angle glaucoma.
  • History of or intolerance to aerosol medications, salbutamol or glycopyrrolate or any of its /components, anticholinergic agents, or sympathomimetic amines.
  • Pulmonary rehabilitation unless such treatment has been stable from 4 weeks prior to Screening (Visit 1) and remains stable during the study. Pulmonary rehabilitation programs should not be started or completed during participation in the study.
  • Major surgery (requiring general anesthesia) in the 6 weeks prior to Screening, lack of full recovery from surgery at Screening, or planned surgery through the end of the study.
  • History of or current of any organ system, treated or untreated within the past 5 years, except for localized basal or squamous cell carcinoma of the skin.
  • Current or history of drug or alcohol abuse within the past 5 years.
  • Estimated (eGFR) \< 30 mL/min.
  • Women who are breast feeding.
  • Use of an experimental drug within 30 days or within 5 half-lives of Screening, whichever is longer, and/or participation in a study treatment-free follow-up phase of a clinical study within 30 days prior to Screening.
  • Use of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical study within 30 days prior to Screening.
  • Affiliation with the investigator site, including an Investigator, Sub-Investigator, study coordinator, study nurse, other employee of participating investigator or study site or a family member of the aforementioned.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Dose Level A

    The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to

    Drug: Glycopyrrolate (85 μg)

  • Experimental
    Dose Level B

    The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to

    Drug: Glycopyrrolate (42.5 μg)

  • Experimental
    Dose Level C

    The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to

    Drug: Glycopyrrolate (14 μg)

  • Placebo comparator
    Dose Level D

    The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: Baseline (pre-dose for each treatment period) and Day 7

Secondary outcomes

  1. Change From Average Baseline FEV1 to Average Peak FEV1 Measured Over 4 Hours

    Time frame: Baseline (pre-dose for each treatment period) and Day 7

  2. Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)

    The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters.

    Time frame: Baseline (pre-dose for each treatment period) and Day 7

  3. Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h)

    The endpoint is measured as AUC/12 hour time interval resulting in an average volume measure in liters.

    Time frame: Baseline (pre-dose for each treatment period) and Day 7

  4. Change From Average Baseline FEV1 to Evening Trough FEV1

    Time frame: Baseline (pre-dose for each treatment period) and Day 7

  5. Change From Average Baseline FEV1 to Peak FEV1 Measured Over 4 Hours After First Dose

    Time frame: Baseline (pre-dose) and Day 1

  6. Change From Average Baseline FEV1 to Average FEV1 AUC0-4h Measured After First Dose

    The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters.

    Time frame: Baseline (pre-dose) and Day 1

  7. Number of Treatment Emergent Adverse Events (TEAEs)

    Time frame: From first dose through the follow-up contact (approximately 8 weeks per participant). Overall safety data was collected for 5 months total.

  8. Glycopyrronium Free Base AUC0-12h

    Time frame: After morning dose Day 7

  9. Glycopyrronium Free Base Maximum Plasma Drug Concentration (Cmax)

    Time frame: After morning dose Day 7

  10. Glycopyrronium Free Base Time to Maximum Plasma Drug Concentration (Tmax)

    Time frame: After morning dose Day 7

07

Results

Posted Feb 9, 2026

Participant flow

Demographic and baseline characteristics are presented by sequence assignment based on which treatment sequence the participant was randomized to. Each treatment sequence was comprised of four treatment periods with a different dose level being received during each period. Therefore, each participant received each dose and there is no demographic or baseline data based dose alone.

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started12111211
Completed1011119
Not completed2012
Withdrew: Adverse event0001
Withdrew: Lost to follow-up0001
Withdrew: Not wanting further contact1000
Withdrew: Withdrawal of consent1000
Withdrew: Withdrawal due to hurricane0010

Outcome measures

PrimaryChange From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1)
Time frame:
Baseline (pre-dose for each treatment period) and Day 7
Reported as:
Least squares mean · Liters
Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1)
LitersDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1)0.0525 ± 0.021250.0393 ± 0.021350.0115 ± 0.02069-0.0287 ± 0.02029
SecondaryChange From Average Baseline FEV1 to Average Peak FEV1 Measured Over 4 Hours
Time frame:
Baseline (pre-dose for each treatment period) and Day 7
Reported as:
Least squares mean · Liters
Change From Average Baseline FEV1 to Average Peak FEV1 Measured Over 4 Hours
LitersDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
Change From Average Baseline FEV1 to Average Peak FEV1 Measured Over 4 Hours0.2333 ± 0.023040.2042 ± 0.023140.1568 ± 0.022430.0520 ± 0.02200
SecondaryChange From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)

The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters.

Time frame:
Baseline (pre-dose for each treatment period) and Day 7
Reported as:
Least squares mean · Liters
Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)
LitersDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)0.0969 ± 0.020370.0693 ± 0.020460.0418 ± 0.01984-0.0403 ± 0.01945
SecondaryChange From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h)

The endpoint is measured as AUC/12 hour time interval resulting in an average volume measure in liters.

Time frame:
Baseline (pre-dose for each treatment period) and Day 7
Reported as:
Least squares mean · Liters
Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h)
LitersDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h)0.0916 ± 0.020060.0656 ± 0.020310.0338 ± 0.02039-0.0449 ± 0.01927
SecondaryChange From Average Baseline FEV1 to Evening Trough FEV1
Time frame:
Baseline (pre-dose for each treatment period) and Day 7
Reported as:
Least squares mean · Liters
Change From Average Baseline FEV1 to Evening Trough FEV1
LitersDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
Change From Average Baseline FEV1 to Evening Trough FEV10.0652 ± 0.020540.0569 ± 0.020660.0091 ± 0.02115-0.0484 ± 0.01996
SecondaryChange From Average Baseline FEV1 to Peak FEV1 Measured Over 4 Hours After First Dose
Time frame:
Baseline (pre-dose) and Day 1
Reported as:
Least squares mean · Liters
Change From Average Baseline FEV1 to Peak FEV1 Measured Over 4 Hours After First Dose
LitersDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
Change From Average Baseline FEV1 to Peak FEV1 Measured Over 4 Hours After First Dose0.2117 ± 0.017860.1872 ± 0.017980.1643 ± 0.016750.0730 ± 0.01716
SecondaryChange From Average Baseline FEV1 to Average FEV1 AUC0-4h Measured After First Dose

The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters.

Time frame:
Baseline (pre-dose) and Day 1
Reported as:
Least squares mean · Liters
Change From Average Baseline FEV1 to Average FEV1 AUC0-4h Measured After First Dose
LitersDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
Change From Average Baseline FEV1 to Average FEV1 AUC0-4h Measured After First Dose0.1377 ± 0.014980.1027 ± 0.015070.0859 ± 0.014050.0000 ± 0.01439
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)
Time frame:
From first dose through the follow-up contact (approximately 8 weeks per participant). Overall safety data was collected for 5 months total.
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events (TEAEs)
EventsDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
Number of Treatment Emergent Adverse Events (TEAEs)138715
SecondaryGlycopyrronium Free Base AUC0-12h
Time frame:
After morning dose Day 7
Reported as:
Mean · h*pg/mL
Glycopyrronium Free Base AUC0-12h
h*pg/mLDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)
Glycopyrronium Free Base AUC0-12h256 ± 187.7108 ± 66.2238.4 ± 18.25
SecondaryGlycopyrronium Free Base Maximum Plasma Drug Concentration (Cmax)
Time frame:
After morning dose Day 7
Reported as:
Mean · pg/mL
Glycopyrronium Free Base Maximum Plasma Drug Concentration (Cmax)
pg/mLDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)
Glycopyrronium Free Base Maximum Plasma Drug Concentration (Cmax)53.7 ± 38.4624.7 ± 13.879.27 ± 5.354
SecondaryGlycopyrronium Free Base Time to Maximum Plasma Drug Concentration (Tmax)
Time frame:
After morning dose Day 7
Reported as:
Median · hours
Glycopyrronium Free Base Time to Maximum Plasma Drug Concentration (Tmax)
hoursDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)
Glycopyrronium Free Base Time to Maximum Plasma Drug Concentration (Tmax)0.33 (0 to 1.63)0.33 (0 to 0.77)0.43 (0.25 to 1.25)

Adverse events

Collected over Adverse event data was collected over a 5-month period, however individual participant data was collected only for 8 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level A Glycopyrrolate (85 μg)0/40 (0%)2/40 (5%)0/40 (0%)
Dose Level B Glycopyrrolate (42.5 μg)0/40 (0%)1/40 (2.5%)0/40 (0%)
Dose Level C Glycopyrrolate (14 μg)0/41 (0%)0/41 (0%)0/41 (0%)
Dose Level D (Placebo)0/43 (0%)1/43 (2.3%)0/43 (0%)
Most frequent serious events
Most frequent serious events
EventDose Level A Glycopyrrolate (85 μg)Dose Level B Glycopyrrolate (42.5 μg)Dose Level C Glycopyrrolate (14 μg)Dose Level D (Placebo)
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders2/400/400/411/43
CARDIAC FAILURE CONGESTIVECardiac disorders1/400/400/410/43
INJURYInjury, poisoning and procedural complications0/401/400/410/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sequence 1Sequence 2Sequence 3Sequence 4Total
Mean63.5 ± 7.1568.7 ± 4.5462.5 ± 9.1766.1 ± 6.2865.1 ± 7.24
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
Female867728
Male455418
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
White99121040
Black32016
Asian00000
American Indian or Alaska Native00000
Native Hawaiian or Other Pacific Islander00000
Other00000
Multiple00000
Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
HISPANIC OR LATINO10001
NOT HISPANIC OR LATINO101112942
NOT REPORTED10023
Region of Enrollment
Region of Enrollment(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
United States1211121146
Body mass index
Body mass index(kg/m^2)Sequence 1Sequence 2Sequence 3Sequence 4Total
Mean29.68 ± 6.28429.04 ± 2.36328.98 ± 9.09827.55 ± 4.47328.83 ± 6.016
Childbearing potential
Childbearing potential(Participants)Sequence 1Sequence 2Sequence 3Sequence 4Total
Yes00000
No867728
08

Study locations

7 sites
  • Clinical Research of West Florida Inc - Clearwater
    Clearwater, Florida 33765, United States
  • Clinical Research of West Florida Inc - Tampa
    Tampa, Florida 33606, United States
  • Midwest Chest Consultants PC
    Saint Charles, Missouri 63301, United States
  • American Health Research Inc
    Charlotte, North Carolina 28277, United States
  • Velocity Clinical Research - Greenville
    Greenville, South Carolina 29615, United States
  • Velocity Clinical Research - Spartanburg
    Spartanburg, South Carolina 29303, United States
  • Velocity Clinical Research - Union
    Union, South Carolina 29379, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jan 2025, 4 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 120 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2024
First posted
Aug 9, 2024
StartActual
Aug 16, 2024
Primary completionActual
Jan 2, 2025
CompletionActual
Jan 8, 2025
Results first posted
Feb 9, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06545500
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Aug 16, 2024
Primary completion
Jan 2, 2025
Completion
Jan 8, 2025
Results posted
Feb 9, 2026
Last update
Feb 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion